Collins Helen Louise's Form 4 filing
Enliven Therapeutics, Inc.ELVN · filed Mar 11, 2026
- Accession no.
- 0001701247-26-000003
- Filed
- Mar 11, 2026
- Trade date
- Mar 9-10, 2026
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Checked
This filing lists 4 non-derivative transactions and 2 derivative transactions. Open-market sales total $1.20M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Collins Helen LouiseCIK 0001701247 | Officer (CHIEF MEDICAL OFFICER) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 9, 2026 | Common Stock | MOption exerciseAcquired | +29,871 | $2.48 | +$74,080.08 | 54,871 | Direct | |
| Mar 9, 2026 | Common Stock | SSaleDisposed | −29,871 | $30.02F3 | −$896,727.42 | 25,000 | Direct | |
| Mar 10, 2026 | Common Stock | MOption exerciseAcquired | +10,129 | $2.48 | +$25,119.92 | 35,129 | Direct | |
| Mar 10, 2026 | Common Stock | SSaleDisposed | −10,129 | $30.19F5 | −$305,794.51 | 25,000 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 9, 2026 | Common Stock | MOption exerciseDisposed | −29,871 | $0.00 | $0 | 191,397 | Direct | |
| Mar 10, 2026 | Common Stock | MOption exerciseDisposed | −10,129 | $0.00 | $0 | 181,268 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F3
This transaction was executed in multiple trades at prices ranging from $30.00 to $30.10. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
Referenced by the price of 1 transaction in Table I.
- F5
This transaction was executed in multiple trades at prices ranging from $30.00 to $30.56. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
Referenced by the price of 1 transaction in Table I.